decentralized digital currency Top Knowledge graph

Deputy Director Huang Huabo attended the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group. On December 12, 2024, the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group was held in Beijing. Huang Huabo, chairman of the working group, member of the party group and deputy director of the National Health Insurance Bureau, attended and spoke. The symposium summarized the work results of the National Working Group on Medical Security Standardization in 2024, and discussed the work in 2025, the five-year development plan of medical security standardization, the framework system and relevant medical insurance standards. Huang Huabo pointed out that in 2024, with the guidance of the National Standards Committee and the support of the bureau party group, all the work of the working group was smoothly promoted through the joint efforts of all members and relevant units inside and outside the bureau. In 2025, the high-quality development of medical insurance put forward higher requirements for medical insurance standardization. It is necessary to further strengthen the sense of responsibility, professionalism and cooperation, accelerate the construction of medical insurance standardization team, and play a supporting role for the high-quality development of medical insurance. (National Medical Insurance Bureau)Yingli shares: Yingli shares increased capital by 80 million yuan to its holding subsidiary. Yingli shares announced that the company and Shanghai Moqin Intelligent Technology Co., Ltd. increased capital to Nanchang Yingli Precision Manufacturing Co., Ltd., with a total capital increase of 80 million yuan, of which Yingli shares increased capital by 67 million yuan in cash and Shanghai Moqin increased capital by 13 million yuan in cash. After this capital increase, the registered capital of Nanchang Yingli will increase from 20 million yuan to 100 million yuan. After the capital increase is completed, Yingli shares hold 80% of the shares of Nanchang Yingli and Shanghai Moqin holds 20% of the shares. This capital increase does not constitute a connected transaction and does not need to be submitted to the company's shareholders' meeting for consideration.Shanghai Gold Exchange: the settlement price of NYAuTN12 contract in Shanghai New Zealand was 627.85 yuan/gram. On December 13th, Shanghai Gold Exchange issued a notice saying that NYAuTN12 contract in Shanghai New Zealand was settled on December 13th, 2024. The details of the settlement of the contract are as follows: the settlement price of NYAuTN12 contract in Shanghai New Zealand was 627.85 yuan/gram.

On the 13th, caustic soda dropped by 3.03%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract caustic soda 2501 closed, with a turnover of 57,100 lots. The position data showed that the top 20 seats were clear, and the difference position was 1,383 lots. The total contract turnover of caustic soda futures was 94,800 lots, an increase of 27,900 lots over the previous day. The first 20 seats in the contract held 71,100 lots, an increase of 2,202 lots over the previous day. Short positions in the top 20 seats of the contract were 72,700 lots, an increase of 1,157 lots over the previous day. (Sina Futures)Anhui procuratorate prosecuted Huawei Yu, the former deputy general manager of Anhui Investment Group Holding Co., Ltd., for allegedly accepting bribes. According to the highest inspection news, a few days ago, Huawei Yu, the former party member and deputy general manager of Anhui Investment Group Holding Co., Ltd., was suspected of accepting bribes, and the Huainan Municipal People's Procuratorate filed a public prosecution with the Huainan Intermediate People's Court according to law after the jurisdiction designated by the Anhui Provincial People's Procuratorate. The case is being further processed. At the stage of examination and prosecution, the procuratorial organ informed the defendant Huawei Yu of his litigation rights according to law, interrogated the defendant according to law and listened to the opinions of defenders. The People's Procuratorate of Huainan City charged that the defendant Huawei Yu, as a national staff member, used the convenience of his position and the convenience of his authority or position to seek benefits for others through the actions of other national staff members, and illegally accepted other people's property alone or in collusion with others. The amount was extremely huge, so he should be investigated for criminal responsibility for accepting bribes according to law.Barclays: The Central Economic Work Conference released more signals of policy support, which was held in Beijing from December 11th to 12th. The Barclays research team said that the Central Economic Work Conference provided more forward-looking guidance and released more policy support signals. Barclays said that on the whole, the meeting made it clear that "stable economic growth should be maintained next year" and emphasized "implementing more active macro policies" and "vigorously boosting consumption". The agency believes that regulators are more likely to introduce policies in a gradual manner. At the same time, when measuring the rhythm, scale and composition of the next round of measures, we should focus on the development and changes of real estate and stock market. Barclays expects that a more specific financial plan will be announced in March next year. In terms of monetary policy, the meeting proposed to implement a "moderately loose monetary policy". Barclays believes that this change in wording and position has released a positive signal, especially considering the current environment, it is expected that the central bank may cut interest rates significantly in the future. (SSE)

Jilin procuratorate prosecuted Jin Chunshan's suspected bribery case according to law. Recently, Jin Chunshan (deputy department level), the former party secretary and procurator-general of Yanbian People's Procuratorate of Jilin Province, was under the jurisdiction of Jilin Provincial People's Procuratorate, and the Liaoyuan People's Procuratorate filed a public prosecution with Liaoyuan Intermediate People's Court according to law. The case is being further processed. In the stage of examination and prosecution, the procuratorate informed the defendant Jin Chunshan of his litigation rights according to law, interrogated the defendant according to law and listened to the opinions of the defenders. The People's Procuratorate of Liaoyuan City sued the accusation that the defendant Jin Chunshan took advantage of his position as the county magistrate of Wangqing County, the deputy secretary and mayor of Hunchun Municipal Committee, and the party secretary and procurator-general of Yanbian People's Procuratorate to seek benefits for the relevant units and individuals in matters such as project contracting and work adjustment, and illegally accepted other people's property, with a huge amount. According to law, he should be investigated for criminal responsibility for accepting bribes.The "hot" power of the ice and snow economy is infinite. The sales of ice and snow products in Yiwu are hot. With the new round of cold air coming, the cooling mode has been started again in many places across the country. The low temperature weather promotes the warming of ice and snow movement in many places, and the "heat" of ice and snow economy is booming. In Yiwu, Zhejiang, the sales of ice and snow products are hot. (Xinhua News Agency)Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.